RSSDrug Development

Interactive Voice Response and Text-based Self-report Versions of the Electronic Columbia-Suicide Severity Rating Scale Are Equivalent

Interactive Voice Response and Text-based Self-report Versions of the Electronic Columbia-Suicide Severity Rating Scale Are Equivalent

| April 1, 2017 | 0 Comments

by Chad Gwaltney, PhD; James C Mundt, PhD; John H. Greist, MD; Jean Paty, PhD; and Brian Tiplady, PhD  Dr. Gwaltney is with Gwaltney Consulting, Westerly, Rhode Island (with ERT Inc. during the time of this study); Dr. Mundt is with ePRO Research Consulting, LLC, Sauk City, Wisconsin; Dr. Greist is Professor Emeritus of Psychiatry, University […]

Continue Reading

CNS Summit 2016 Abstracts of Poster Presentations

CNS Summit 2016 Abstracts of Poster Presentations

| February 1, 2017 | 0 Comments

Innov Clin Neurosci. 2017;14(1–2)3–23 A MESSAGE FROM THE EDITOR Dear Colleagues: Welcome to the annual CNS Summit Abstracts of Poster Presentations supplement to Innovations in Clinical Neuroscience. We are pleased to provide you with this reference guide to some of the innovative research that was presented during CNS Summit 2016, which was held October 27 […]

Continue Reading

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

| February 1, 2017 | 0 Comments

by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, PhD; Suzanne Hendrix, PhD; Enchi Liu, PhD; David A. Loewenstein, PhD; Glenn Morrison, MSc, PhD; Leslie Shinobu, PhD; Keith Wesnes, BSc, PhD, FSS, CPsychol, FBPsS; and Philip D. Harvey, PhD Dr. Posner is with Pfizer Inc., New York, New York; Drs. Curiel, Loewenstein, and Harvey […]

Continue Reading

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

| February 1, 2017 | 0 Comments

by Philip D. Harvey, PhD; Stephanie Cosentino, PhD; Rosie Curiel, PhD; Terry E. Goldberg, PhD; Jeffrey Kaye, MD; David Loewenstein, PhD; Daniel Marson, PhD, JD; David Salmon, PhD; Keith Wesnes, PhD; and Holly Posner, MD Drs. Harvey, Curiel, and Loewenstein are with the University of Miami Leonard Miller School of Medicine, Department of Psychiatry and Behavioral Sciences, Miami, Florida; […]

Continue Reading

Editor’s Message: September–October 2016 Issue Highlights

Editor’s Message: September–October 2016 Issue Highlights

| October 9, 2016 | 0 Comments

Dear Colleagues: Welcome to the September-October 2016 issue of Innovations in Clinical Neuroscience (ICNS). As the official journal of the CNS Summit, the International Society for CNS Drug Development (ISCDD), and the International Society for CNS Clinical Trials and Methodology (ISCTM), an important part of our editorial mission is to accelerate and enhance the development […]

Continue Reading

Performance, Reliability, Usability, and Safety of the ID-Cap System for Ingestion Event Monitoring in Healthy Volunteers:  A Pilot Study

Performance, Reliability, Usability, and Safety of the ID-Cap System for Ingestion Event Monitoring in Healthy Volunteers: A Pilot Study

| October 9, 2016 | 0 Comments

by Glen P. Flores, PhD; Brian Peace, BS; Tony C. Carnes, PhD; Susan L. Baumgartner, PharmD, MBA; D. Eric Buffkin, Jr., MBA; Neil R. Euliano, PhD; and Larry N. Smith, MD, FACS Drs. Flores, Carnes, Euliano, Mr. Peace, and Mr. Buffkin are with etectRx, Inc. in Newberry, Florida; and Drs. Baumgartner and Smith are from […]

Continue Reading

Editor’s Message—Issue Highlights, July–August 2016

Editor’s Message—Issue Highlights, July–August 2016

| August 1, 2016 | 0 Comments

Dear Colleagues: Welcome to the July–August 2016 issue of Innovations in Clinical Neuroscience. We start this issue with an interesting study by MacEwan et al titled, “Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.” Here, the authors assessed the level of private and public investment in research and development […]

Continue Reading